Vilazodone
Viibryd (vilazodone) is a prescription antidepressant used to treat major depressive disorder in adults. It works through a dual mechanism as a selective serotonin reuptake inhibitor (SSRI) combined with partial agonism at serotonin 5-HT1A receptors, which may help improve mood and reduce anxiety symptoms. This medication is typically used when other treatments have not been effective or tolerated.
Viibryd is an antidepressant medication for adults with major depressive disorder that works through serotonin-related mechanisms.
Key facts at a glance
- RxNorm
- 1086773
- Generic
- Viibryd
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Viibryd is FDA-approved for the treatment of major depressive disorder (MDD) in adults. It may be prescribed when symptoms of depression significantly impact daily functioning, including persistent sadness, loss of interest in activities, changes in sleep or appetite, and difficulty concentrating.
Viibryd works through a dual mechanism: it acts as a selective serotonin reuptake inhibitor (SSRI) to increase serotonin levels in the brain, while also functioning as a partial agonist at serotonin 5-HT1A receptors. This combination may provide enhanced serotonergic activity and potentially faster onset of action compared to traditional SSRIs.
Viibryd is typically taken once daily with food to maximize absorption. Common side effects may include nausea, diarrhea, and headache. As with other antidepressants, it carries a boxed warning about increased risk of suicidal thoughts and behaviors in young adults under 25. It should not be taken with MAO inhibitors or within 14 days of stopping such medications. Patients should be monitored for worsening depression, unusual behavior changes, or emergence of suicidal ideation, especially during initial treatment.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 26, 2026. · Read our editorial policy